Page 19 - Jun Lee News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: Scientists at SLAC National Accelerator Laboratory used an improved X-ray technique to explore exotic states of matter in an unconventional superconductor that conducts electricity with 100% efficiency at relatively high... view more  Credit: Jun-Sik Lee/SLAC National Accelerator Laboratory Unconventional superconductors contain a number of exotic phases of matter that are thought to play a role, for better or worse, in their ability to conduct electricity with 100% efficiency at much higher temperatures than scientists had thought possible - although still far short ...

One of two customers involved in an attack inside of a beauty supply store on St. Patrick’s Day has been indicted on a hate crime charge, District Attorney Kim Ogg announced Friday.

March 2, 2021 at 1:24 pm Exclusive Interview with Nabis Co-Founder and President Jun Lee Nabis is a technology-powered, third party-cannabis distributor serving the California market. Co-Founder and CEO Vincent Ning spoke with New Cannabis Ventures in 2018, and Co-Founder and President Jun Lee provided an update. He spoke with New Cannabis Ventures about the Nabis network, expanding beyond California and creating a different kind of distribution model. The audio of the entire conversation is available at the end of this written summary. The Nabis Team Lee has a background in technology. ...

Share this article Share this article PARAMUS, N.J., Feb. 10, 2021 /PRNewswire/ -- Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received both Rare Pediatric Disease and Orphan Drug Designations for the treatment of Krabbe Disease (a.k.a. Globoid Cell Leukodystrophy) with PLX-300 from the U.S. Food and Drug Administration (FDA). Krabbe disease (KD) is a rare, heritable metabolic genetic disorder that affects approximately one in 100,000 individuals in the United States. KD is caused by de...

Share this article Share this article PARAMUS, N.J., Dec. 18, 2020 /PRNewswire/ -- Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received from the U.S. Food and Drug Administration (FDA) both Rare Pediatric Disease and Orphan Drug Designations for the treatment of Niemann Pick Disease Types A and B, known as Acid Sphingomyelinase Deficiency with PLX-300. Niemann Pick Disease (NPD) Types A and B is a group of ultra-rare and fatal pediatric neurodegenerative disorders caused by defects in ...